Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-03-29
2011-03-29
Kolker, Daniel E (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S324000, C530S326000, C514S017700, C514S021300
Reexamination Certificate
active
07915226
ABSTRACT:
Methods of suppressing the activation of microglial cells in the Central Nervous System (CNS), methods of ameliorating or treating the neurological effects of cerebral ischemia or cerebral inflammation, and methods of combating specific diseases that affect the CNS by administering a compound that binds to microglial receptors and prevents or reduces microglial activation are described. Also described are methods of screening compounds for the ability to suppress or reduce microglial activation.
REFERENCES:
patent: 4902505 (1990-02-01), Pardridge et al.
patent: 5017566 (1991-05-01), Bodor
patent: 5182364 (1993-01-01), Dyer et al.
patent: 5204327 (1993-04-01), Kiyota et al.
patent: 5473039 (1995-12-01), Dyer et al.
patent: 5604198 (1997-02-01), Poduslo et al.
patent: 5686416 (1997-11-01), Kozarich et al.
patent: 6245751 (2001-06-01), Crutcher et al.
patent: 6455553 (2002-09-01), Werner et al.
patent: 6605588 (2003-08-01), Lee et al.
patent: WO 92/10512 (1992-06-01), None
patent: WO 95/06456 (1995-03-01), None
patent: WO 97/14437 (1997-04-01), None
patent: WO 98/01101 (1998-01-01), None
patent: WO 99/08701 (1999-02-01), None
patent: WO 99/16464 (1999-04-01), None
patent: WO 99/45950 (1999-09-01), None
patent: WO 03/026479 (2003-04-01), None
patent: WO 03/026479 (2003-04-01), None
McEwen, B.S. “Allostasis, Allostatic Load, and the Aging Nervous System: Role of Excitatory Amino Acids and Excitotoxicity”, Neurochemical Research, vol. 25: 1219-1231 (2000).
Aono, et al., “Protective Effects of Peptides Corresponding to the Receptor Binding Region of Apolipoprotein E on NMDA Excitotoxicity in Primary Neuronal-Glial Cultures”, Trip Report: 31stAnnual Meeting of the Society for Neuroscience, San Diego, California (Nov. 2001).
Barger, et al., “Microglial Activation by Alzheimer Amyloid Precursor Protein and Modulation by Apolipoprotein E”, Nature 388: 878-881 (Aug. 1997).
Benazzouz, et al., “Riluzole Prevents MPTP-induced Parkinsonism in the Rhesus Monkey: A Pilot Study,”Eur. J. Pharmacol. 284:299-307 (1995).
Bowie, et al., “Deciphering the message in protein sequences: tolerance to amino acid substitutions”, Science, 247: 1306-1310 (1990).
Cardin, et al., “Inhibition of Lymphocyte Proliferation b Synthetic Peptides Homologous to Human Plasma Apolipoproteins B and E”, Biochemical and Biophysical Research Communications, 154: 741-745 (Jul. 1998).
Champe, et al., “IV. Tertiary Structure of Globular Proteins,” “V. Quaternary Structure of Proteins,” “VI Denaturation of Proteins,” and “VII. Protein Misfolding,” pp. 18-21 inLippincott's Illustrated Reviews: Biochemistry 3rd Ed. Lippincott Williams & Wilkins, Philadelphia, Pennsylvania, USA (2005).
Chen, et al., “Motor and Cognitive Deficits in Apolipoprotein E Deficient Mice After Closed Head Injury,”Neuroscience 80:1255-1262 (1997).
Christie, et al., “Expression of the Very Low-Density Lipoprotein Receptor (VLDL-r), an Apolipoprotein-E Receptor, in the Central Nervous System and in Alzheimer's Disease”, Journal of Neuropathology and Experimental Neurology, 55(4): 491-498 (1996).
Clay, et al., “Localization of a Domain in Apolipoprotein E with Both Cytostatic and Cytotoxic Activity”, Biochemistry, 34: 11142-11151 (1995).
Crutcher, et al., “Neurite degeneration elicited by apolipoprotein E peptides”, Experimental Neurology 130(1):120-126 (1994).
Dong, et al., “Enhanced binding activity of an apolipoprotein E mutant, APO E5, to LDL receptors on human fibroblasts”, Biochemical & Biophysical Research Communications 168(2):409-414 (Apr. 1990).
Dong, et al., “Site-directed mutagenesis of an apolipoprotein E mutant, apo E5(Glu3—Lys) and its binding to low density lipoprotein receptors”, Biochemical & Biophysical Research Communications 187(2):1180-1186 (Sep. 1992).
Dyer, et al., “A Synthetic Peptide Mimetic of Plasma Apolipoprotein E that Binds the LDL Receptor”, Journal of Biological Chemistry, 266: 22803-22806 (Dec. 1991).
Dyer, et al., “Only Multimers of a Synthetic Peptide of Human Apolipoprotein E Are Biologically Active”, Journal of Biological Chemistry, 266: 15009-15015 (1991).
Gordon, et al., “Derangement in Stress Response of Apolipoprotein E-deficient Mice,”Neuroscience Letters206:212-214 (1996).
Holtzman, et al., “Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived neuronal cell line”, Proc. Natl. Acad. Sci. USA, 92: 9480-9484 (1995).
Innerarity, et al., “Binding of arginine-rich (E) apoprotein after recombination with phospholipid vesicles to the low density lipoprotein receptors of fibroblasts”, Journal of Biological Chemistry 254(10):4186-4190 (1979).
International Search Report for PCT/US99/05221 (mailed Nov. 3, 1999).
Jordan, et al., “Isoform-Specific Effect of Apolipoprotein E on Cell Survival and β-Amyloid-induced Toxicity in Rat Hippocampal Pyramidal Neuronal Cultures,”J. Neurosci. 18:195-204 (1998).
Lalazar, et al., “Site-specific Mutagenesis of Human Apolipoprotein E”, Journal of Biological Chemistry, 263: 3542-3545 (1988).
Laskowitz, et al., “Endogenous apolipoprotein E suppresses LPS-stimulated microglial nitric oxide production”, Neuroreport. 9(4):615-618 (1998).
Laskowitz, et al., “Apolipoprotein E and the CNS response to injury”, Journal of Cerebral Blood Flow & Metabolism 18(5): 465-471 (1998).
Laskowitz, et al., “Apolipoprotein E suppresses glial cell secretion of TNF alpha”, Journal of Neuroimmunology 76(1-2):70-74, (1997).
Laskowitz, et al., “Apolipoprotein E-deficient mice have increased susceptibility to focal cerebral ischemia”, Journal of Cerebral Blood Flow & Metabolism 17(7):753-758 (1997).
Laskowitz, et al., “Downregulation of Microglial Activation by Apolipoprotein E and ApoE-Mimetic Peptide”, Experimental Neurology, 167: 74-85 (2001).
Ludwig, “Supplementary European Search Report,” 3 pages, from EP Appl. No. 02775888.7, European Patent Office, Munich, Germany (mailed Mar. 9, 2007).
Marzolo, et al., “Expression of α2-Macroglobulin Receptor/ Low Density Lipoprotein Receptor-Related Protein (LRP) in Rat Microglial Cells,”J. Neurosci. Res. 60:401-411 (2000).
Mickle, et al., “Genotype-phenotype relationships in cystic fibrosis”, Med. Clin. North Am., 84 (3): 597-607 (May 2000).
Misra, et al., “Apolipoprotein E and Mimetic Peptide Initiate a Calcium-Dependent Signaling Response in Macrophages”, Journal Leukocyte Bio. 70: 677-683 (2001).
Mrak, et al., “Glial Cytokines in Alzheimer's Disease: Review and Pathogenic Implications”, Hum. Pathol. 26: 816-823 (Aug. 1995).
Pardridge, “Chapter 12: Blood-brain barrier peptide transport and peptide delivery to the brain, Peptide-based drug design”, Ed. Taylor et al., American Chemical Society, 265-296 (1995).
Tolar, et al., “Truncated Apolipoprotein E (ApoE) Causes Increased Intracellular Calcium and May Mediate ApoE Neurotoxicity,”J. Neuroscience19(16): 7100-7110 (1999).
Vitek, et al., “Modulation of nitric oxide production in human macrophages by apolipoprotein-E and amyloid-beta peptide”, Biochemical & Biophysical Research Communications 240(2):391-394 (1997).
Voet, et al., Biochemistry, John Wiley & Sons, Inc., 126-128 and 228-234 (1990).
Weisgraber, et al., “The receptor-binding domain of human apolipoprotein E. Monoclonal antibody inhibition of binding”, Journal of Biological Chemistry 258(20):12348-12354 (1983).
Yan, et al., “Two-amino acid molecular switch in an epithelial morphogen that regulates binding to two distinct receptors”, Science, 290: 523-527 (2000).
Zielasek, et al., Advances in Neuroimmunology, 6
Laskowitz Daniel T.
Matthew William D.
McMillian Michael
Cognosci, Inc.
Cooley LLP
Emch Gregory S
Kolker Daniel E
LandOfFree
Methods of suppressing microglial activation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of suppressing microglial activation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of suppressing microglial activation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2741432